This segment focuses on the development and commercialization of advanced clinical diagnostics specifically for kidney transplant patients. Research and development activities include the creation and validation of prognostic and diagnostic tests, such as Tutivia™ and Clarava™, which utilize RNA signature biomarkers to assess the risk of rejection and monitor transplant health. Technologies employed involve advanced molecular biology techniques, including RNA sequencing and analysis. The primary therapeutic area is nephrology, with the goal of improving patient outcomes by enabling earlier and more accurate detection of transplant rejection and other complications. This segment aims to provide clinicians with tools to personalize patient care, reduce the incidence of graft failure, and improve long-term survival rates. Market positioning is centered on providing innovative solutions in a niche market with high unmet medical needs. Future opportunities include expanding the test portfolio and geographic reach, as well as exploring partnerships with leading transplant centers and pharmaceutical companies. Regulatory and clinical aspects involve rigorous clinical validation studies and seeking approvals from relevant regulatory bodies. The company has partnerships with Illumina and FBB Biomed for research and laboratory services.